Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus.
Black KJ, Nasrallah H, Isaacson S, Stacy M, Pahwa R, Adler CH, Alva G, Cooney JW, Kremens D, Menza MA, Meyer JM, Patkar AA, Simuni T, Morrissette DA, Stahl SM.
Black KJ, et al. Among authors: meyer jm.
CNS Spectr. 2018 Dec;23(6):402-413. doi: 10.1017/S1092852918001359.
CNS Spectr. 2018.
PMID: 30588905
Review.